A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin
What is the efficacy and safety of chemotherapy drug, brentuximab vedotin, in front-line
therapy of Hodgkin Lymphoma in adults age 60 and above?
Basic Study Information
Purpose:Study Reference #: ILYM12066
This is an open-label clinical trial designed to evaluate the effectiveness and safety
of brentuximab vedotin, a chemotherapy drug, as front-line therapy of Hodgkin Lymphoma
in adults age 60 and above. It will be given as a single treatment (Part A) or in
combination with dacarbazine (Part B), or in combination with bendamustine (Part C),
or in combination with nivolumab (Part D).
Lead Researcher (Principal Investigator)
Lead Researcher: Jonathan Friedberg, MD
Study Contact Information
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search